Abstract 901
Background
[Fam-] trastuzumab deruxtecan (T-DXd; formerly DS-8201a) is an antibody drug conjugate comprised of a humanized HER2 antibody, cleavable peptide-based linker, and topoisomerase I inhibitor payload (MAAA-1181a; exatecan derivative). MAAA-1181a is a substrate for CYP3A enzymes and OATP1B. T-DXd demonstrated antitumor activity and manageable safety in HER2-expressing/mutated solid tumors (NCT02564900). This study (NCT03383692) assessed the effect of concomitant ritonavir (OATP1B/CYP3A inhibitor) or itraconazole (CYP3A strong inhibitor) on the PK profile of T-DXd and MAAA-1181a.
Methods
Eligible subjects had HER2-expressing (IHC ≥1+ and/or ISH+) unresectable/metastatic solid tumors. T-DXd 5.4 mg/kg was administered IV in 3-week cycles. Ritonavir 200 mg BID (cohort 1) or itraconazole 200 mg QD/BID (cohort 2) were administered from day 17 of cycle 2 to end of cycle 3. Primary endpoints were Cmax and AUC17d. TEAEs and objective tumor response rate (ORR) were secondary endpoints.
Results
Forty subjects were enrolled (17 in cohort 1; 23 in cohort 2). Breast cancer was the most common cancer (42.5%). In the PK analysis set (n = 26; majority of exclusions due to inhibitor drug noncompliance), there was a small increase in AUC17d for MAAA-1181a and T-DXd with concomitant ritonavir or itraconazole (Table). In the safety analysis set (n = 40), 39 (97.5%) had a TEAE, 5 (12.5%) reported ≥1 serious TEAE, and 2 had ILD/pneumonitis (grade ≤3). The most common TEAEs included nausea (80.0%), decreased appetite (55.0%), and constipation (37.5%). TEAE incidence did not increase in cycle 3 vs 2. Confirmed ORR was 15/36 (41.7%) in subjects with measurable tumors at baseline (n = 36).Table:
330P Pharmacokinetics of T-DXd and MAAA-1181a without (cycle 2) and with (cycle 3) concomitant ritonavir (CYP3A/OATP1B inhibitor) or itraconazole (CYP3A strong inhibitor)
Ritonavir | ||||||
---|---|---|---|---|---|---|
Parameters | LS Means | Ratio | 90% CI | |||
C2 | C3 | C3/C2 | Lower | Upper | ||
MAAA-1181a | AUC17d(d*ng/mL)a | 30.2 | 36.6 | 1.215 | 1.078 | 1.370 |
Cmax (ng/mL)b | 8.49 | 8.38 | 0.987 | 0.854 | 1.140 | |
T-DXd | AUC17d(d*ug/mL)a | 623 | 742 | 1.192 | 1.140 | 1.246 |
Cmax (ug/mL)b | 131 | 138 | 1.049 | 0.976 | 1.128 | |
Itraconazole | ||||||
Parameters | LS Means | Ratio | 90% CI | |||
C2 | C3 | C3/C2 | Lower | Upper | ||
MAAA-1181a | AUC17d(d*ng/mL)c | 28.8 | 33.9 | 1.178 | 1.108 | 1.252 |
Cmax (ng/mL)c | 8.43 | 8.78 | 1.042 | 0.917 | 1.184 | |
T-DXd | AUC17d(d*ug/mL)c | 617 | 685 | 1.110 | 1.073 | 1.147 |
Cmax (ug/mL)c | 137 | 140 | 1.025 | 0.963 | 1.091 |
N = 8;
bN = 12;
cN = 14. AUC17d, area under the concentration-time curve from cycle day 1–17; CI, confidence interval; Cmax, maximum plasma concentration; C2, cycle 2; C3, cycle 3; LS, least squares; MAAA-1181a, topoisomerase I inhibitor payload (exatecan derivative) that is released from T-DXd; T-DXd, [fam-] trastuzumab deruxtecan.
Conclusions
There was a small increase in AUC17d for T-DXd and its payload with concomitant ritonavir and itraconazole that did not appear to be clinically meaningful. Efficacy and safety of T-DXd were consistent with previous trials.
Clinical trial identification
NCT03383692.
Editorial acknowledgement
Medical writing and editorial support was provided by Alicia Salinero, PhD; and Stefan Kolata, PhD, of AlphaBioCom, LLC, and funded by Daiichi Sankyo, Co., Ltd.
Legal entity responsible for the study
Daiichi Sankyo, Co., Ltd.
Funding
Daiichi Sankyo, Co., Ltd.
Disclosure
Y. Bang: Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy, Research grant / Funding (institution): Genentech/Roche; Advisory / Consultancy, Research grant / Funding (institution): MSD; Advisory / Consultancy, Research grant / Funding (institution): Merck Serano; Advisory / Consultancy, Research grant / Funding (institution): Bayer; Advisory / Consultancy, Research grant / Funding (institution): BMS; Advisory / Consultancy, Research grant / Funding (institution): Eli Lilly; Advisory / Consultancy, Research grant / Funding (institution): Taiho; Advisory / Consultancy, Research grant / Funding (institution): Daiichi Sankyo; Advisory / Consultancy, Research grant / Funding (institution): Astellas; Advisory / Consultancy, Research grant / Funding (institution): BeiGene; Advisory / Consultancy, Research grant / Funding (institution): Green Cross; Advisory / Consultancy: Samyang Biopharm; Advisory / Consultancy: Hanmi; Advisory / Consultancy, Research grant / Funding (institution): Genexine; Research grant / Funding (institution): GSK; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Boeringer-Ingelheim; Research grant / Funding (institution): MacroGenics; Research grant / Funding (institution): Boston Biomedical; Research grant / Funding (institution): FivePrime; Research grant / Funding (institution): Curis; Research grant / Funding (institution): Takeda; Research grant / Funding (institution): Ono; Research grant / Funding (institution): CKD Pharma. M. Takahashi: Honoraria (self): Chugai; Honoraria (self): AstraZeneca; Honoraria (self): Novartis; Honoraria (self): Pfizer; Honoraria (self): Kyowa Hakko-Kirin; Honoraria (self): Eisai; Honoraria (self): Eli Lilly; Honoraria (self): Taiho; Honoraria (self): Daiichi Sankyo. J. Watanabe: Honoraria (self): Daiichi Sankyo. H. Minami: Honoraria (self), Research grant / Funding (institution), clinical trial: Novartis; Research grant / Funding (institution): Asahi-Kasei Pharma; Research grant / Funding (institution): Astellas; Research grant / Funding (institution), clinical trial: AstraZeneca; Honoraria (self), Research grant / Funding (institution), clinical trial: Bayer; Honoraria (self), Research grant / Funding (institution): Behringer; Honoraria (self), Research grant / Funding (institution), clinical trial: Bristol-Myers Squibb; Honoraria (self): Celgene; Honoraria (self), Research grant / Funding (institution), clinical trial: Chugai; Research grant / Funding (institution), clinical trial: Daiichi Sankyo; Honoraria (self), Research grant / Funding (institution): DaiNihonSumitomo; Honoraria (self), Research grant / Funding (institution): Eizai; Honoraria (self): Janssen; Honoraria (self): Kowa; Honoraria (self), Research grant / Funding (institution): Kyowa-Kirin; Honoraria (self), Research grant / Funding (institution): Lilly; Honoraria (self), Research grant / Funding (institution): Merck Serono; Honoraria (self), Research grant / Funding (institution), clinical trial: MSD; Research grant / Funding (institution): Nihon Shinyaku; Honoraria (self), Research grant / Funding (institution): Nippon Chemiphar; Honoraria (self), Research grant / Funding (institution), clinical trial: Ono Yakuhin; Honoraria (self): Ohtsuka; Honoraria (self), Research grant / Funding (institution), clinical trial: Pfizer; Honoraria (self), Research grant / Funding (institution): Sanofi; Honoraria (self): Shire Japan; Honoraria (self), Research grant / Funding (institution), clinical trial: Taiho; Research grant / Funding (institution): Taisho-Toyama; Honoraria (self), Research grant / Funding (institution): Takeda; Research grant / Funding (institution): Teijin Pharma; Research grant / Funding (institution): Yakult; Honoraria (self): Genomic Health; Research grant / Funding (institution): CSL Behring; Research grant / Funding (institution): Nihon Kayaku; Research grant / Funding (institution): Shionogi. N. Yamamoto: Honoraria (self), Research grant / Funding (institution): Chugai; Research grant / Funding (institution): Taiho; Advisory / Consultancy, Research grant / Funding (institution): Eisai; Honoraria (self), Research grant / Funding (institution): Lilly; Research grant / Funding (institution): Quintiles; Research grant / Funding (institution): Astellas; Honoraria (self), Research grant / Funding (institution): BMS; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Daiichi Sankyo; Honoraria (self), Research grant / Funding (institution): Pfizer; Honoraria (self), Research grant / Funding (institution): Boehringer Ingelheim; Research grant / Funding (institution): Kyowa-Hakko Kirin; Research grant / Funding (institution): Bayer; Honoraria (self), Research grant / Funding (institution): ONO PHARMACEUTICAL CO., LTD; Honoraria (self): Chugai; Honoraria (self): AstraZeneca; Advisory / Consultancy: Otsuka; Advisory / Consultancy, Research grant / Funding (institution): Takeda; Advisory / Consultancy: Cimic; Research grant / Funding (institution): Janssen Pharma; Research grant / Funding (institution): MSD; Research grant / Funding (self): Merck. C. Lin: Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self): Roche; Research grant / Funding (institution): Daiichi Sankyo; Travel / Accommodation / Expenses: BeiGene. T. Fujiki: Full / Part-time employment: Daiichi Sankyo. I. Achiwa: Full / Part-time employment: Daiichi Sankyo. E. Kamiyama: Full / Part-time employment: Daiichi Sankyo. Y. Okuda: Full / Part-time employment: Daiichi Sankyo. C. Lee: Full / Part-time employment: Daiichi Sankyo. S. Takahashi: Honoraria (self), Research grant / Funding (institution): Daiichi Sankyo; Honoraria (self): Novartis; Honoraria (self), Research grant / Funding (institution): MSD; Honoraria (self), Research grant / Funding (institution): Eisai; Honoraria (self), Research grant / Funding (institution): Taiho; Honoraria (self), Research grant / Funding (institution): Chugai; Honoraria (self), Research grant / Funding (institution): Bayer; Honoraria (self), Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Quintiles. All other authors have declared no conflicts of interest.
Resources from the same session
714 - The feasibility and efficacy of gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian insufficiency in patient with malignant ovarian germ cell tumors
Presenter: Min Kyu Kim
Session: Poster Display session 2
Resources:
Abstract
1753 - Ex vivo cytotoxicity and in vivo antitumor activity of a novel highly selective STAT3 inhibitor YHO-1701 for ovarian and endometrial cancer
Presenter: Kosei Hasegawa
Session: Poster Display session 2
Resources:
Abstract
3739 - Mutational landscapes and tumor mutational burden expression in endometrial cancer
Presenter: Yingli Zhang
Session: Poster Display session 2
Resources:
Abstract
2109 - Clinical features and frequency of mismatch repair protein deficiency in ovarian clear cell and endometrioid carcinoma patients.
Presenter: Kazuhiro Takehara
Session: Poster Display session 2
Resources:
Abstract
4554 - Prospective study evaluating white adipose tissue inflammation and clinicopathologic features in endometrial cancer
Presenter: Lea Moukarzel
Session: Poster Display session 2
Resources:
Abstract
3645 - Cancer-specific survival with or without adjuvant chemotherapy in high-risk stage I endometrial cancer
Presenter: Jenny Ko
Session: Poster Display session 2
Resources:
Abstract
3394 - Pembrolizumab in Patients with MSI-H Advanced Endometrial Cancer from the KEYNOTE-158 Study
Presenter: David Omalley
Session: Poster Display session 2
Resources:
Abstract
3388 - Who drops out of cervical cancer screening? Results from the EDIFICE 6 survey
Presenter: Thibault de La Motte Rouge
Session: Poster Display session 2
Resources:
Abstract
2485 - Identification of a RNA-Seq Based Signature to Improve Prognostic for Uterine Sarcoma
Presenter: Jian-Guo Zhou
Session: Poster Display session 2
Resources:
Abstract
1049 - The Effect Of Multiple Interventions For Women At Risk For Cervical Cancer On Their Health Responsibility, Beliefs Regarding Cervical Cancer, And Having Screening: A Randomized Controlled Experiment
Presenter: Busra Altinel
Session: Poster Display session 2
Resources:
Abstract